64Cu-Labeled Aptamers for Tumor-Targeted Radionuclide Delivery
Aptamers are a class of oligonucleotides with high binding affinity and specificity with their targets. Additionally, aptamers are nontoxic, very thermally stable, and able to reversibly undergo denaturation and have a small size. Cancer-related aptamers can be used for tumor-targeted drug delivery, such as to deliver diagnostic and therapeutic radionuclides to target cancers. We describe the process for preparing a 64Cu-labeled modified A10 aptamer to target prostate cancer by conjugating and radiolabeling. The modified A10 aptamer was conjugated with p-SCN-Bn-NOTA as the chelator. Following this, the aptamer can be radiolabeled with the 64Cu radioisotope. NOTA was selected as the chelator of choice due to its commercial availability and widely demonstrated in vivo stability with the 64Cu radioisotope. Using this system, prostate cancer could potentially be targeted for noninvasive imaging using positron emission tomography (PET). Closely following this protocol allows many aptamers to be successfully radiolabeled to accurately and quantitatively trace their distribution in vivo for a wide range of medical applications.
KeywordsAptamer A10 Radionuclide Copper-64 (64Cu) Radiolabel Tumor Delivery
This work was supported by the University of Wisconsin–Madison, the National Institutes of Health (P30CA014520), the Beijing Nova Program (Z171100001117024), and the Beijing Capital Special Development Application Program (Z141107002514159).
- 9.Esposito CL, Cerchia L, Catuogno S, De Vita G, Dassie JP, Santamaria G, Swiderski P, Condorelli G, Giangrande PH, de Franciscis V (2014) Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther 22(6):1151–1163. https://doi.org/10.1038/mt.2014.5CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Bouchard PR, Hutabarat RM, Thompson KM (2010) Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50(1):237–257. https://doi.org/10.1146/annurev.pharmtox.010909.105547CrossRefPubMedGoogle Scholar
- 15.US National Library of Medicine (2017) clinicaltrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03168139?term=NCT03168139&rank=1. Accessed 2 Dec 2017
- 16.US National Library of Medicine (2014) clinicaltrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT01547897?term=NCT01547897&rank=1. Accessed 2 Dec 2017
- 17.US National Library of Medicine (2017) clinicaltrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03364153?term=NCT03364153&rank=1. Accessed 2 Dec 2017
- 20.Li J, Zheng C, Cansiz S, Wu C, Xu J, Cui C, Liu Y, Hou W, Wang Y, Zhang L, Teng I, Yang H-H, Tan W (2015) Self-assembly of DNA nanohydrogels with controllable size and stimuli-responsive property for targeted gene regulation therapy. J Am Chem Soc 137(4):1412–1415. https://doi.org/10.1021/ja512293fCrossRefPubMedPubMedCentralGoogle Scholar
- 22.Taghavi S, HashemNia A, Mosaffa F, Askarian S, Abnous K, Ramezani M (2016) Preparation and evaluation of polyethylenimine-functionalized carbon nanotubes tagged with 5TR1 aptamer for targeted delivery of Bcl-xL shRNA into breast cancer cells. Colloids Surf B Biointerfaces 140(Supplement C):28–39. https://doi.org/10.1016/j.colsurfb.2015.12.021CrossRefPubMedGoogle Scholar
- 25.Jiang D, Im H-J, Sun H, Valdovinos HF, England CG, Ehlerding EB, Nickles RJ, Lee DS, Cho SY, Huang P, Cai W (2017) Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. Eur J Nucl Med Mol Imaging 44(8):1296–1305. https://doi.org/10.1007/s00259-017-3663-yCrossRefPubMedPubMedCentralGoogle Scholar
- 26.Yang Y, Hernandez R, Rao J, Yin L, Qu Y, Wu J, England CG, Graves SA, Lewis CM, Wang P, Meyerand ME, Nickles RJ, X-w B, Cai W (2015) Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proc Natl Acad Sci U S A 112(47):E6525–E6534. https://doi.org/10.1073/pnas.1502648112CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO 2nd, Giangrande PH (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27(9):839–849. https://doi.org/10.1038/nbt.1560CrossRefPubMedPubMedCentralGoogle Scholar